Aimed at those over the age of 12 at risk, the treatment is currently the only authorized treatment for people infected with Omicron.
A new anti-Covid treatment with synthetic antibodies, Xevudy, has been approved by the French health authorities, who consider it promising against infection by Omicron while other drugs have just been withdrawn because of their ineffectiveness against the new variant. Read alsoCovid-19: this treatment that remains effective against Omicron Based on the sotrovimab molecule, it will therefore be, for the time being, the only antibody treatment that can be used after a proven infection with Omicron. Another treatment of this type, Evusheld from AstraZeneca, is also considered effective against Omicron but it is given preventively, especially in people whose body is resistant to vaccination. SEE ALSO – Antivirals, corticosteroids… Dr Benjamin Rossi provides an update on treatments for serious forms Covid-19
Administration by intravenous The High Authority for Health (HAS) “ authorizes early access to a new curative treatment, Xevudy (…) of GSK ”, announced this body in a press release. This medicine is intended for people over the age of 12 who have just been infected with the coronavirus and are considered at risk of a severe form. “It is recommended to administer it within five days of the onset of symptoms”, explains the authority. Xevudy is administered intravenously. It is part of the synthetic antibody treatments, several of which have already been authorized since the start of the pandemic. But the arrival of the Omicron variant, which is more resistant to vaccines and other drugs, has made some of these treatments obsolete. The French health authorities thus ceased at the beginning of January to recommend Ronapreve from Roche in the event of infection with Omicron, even if it remains authorized against Delta, the previous dominant variant. Worse, they completely withdrew Eli Lilly’s bamlanivimab/etesivimab combination from circulation, its results also showing disappointment against Delta. Contrary to these two treatments, Xevudy «has a mechanism of action which makes it possible to hope for the maintenance of its effectiveness on the variants , including the Omicron variant”, explains the HAS. “ In vitro data suggest maintenance of the neutralizing activity of sotrovimab when that of the other available monoclonal antibodies decreases or even disappears”, she explains.
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here